| (Values in U.S. Thousands) | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Orexo Ab (ORXOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Orexo AB is a pharmaceutical company. It develops and improves products and treatments based on proprietary drug delivery technology. Its main products are Abstral, Edluar, Diabact UBT, and Heliprobe System. Abstral is a drug that provides fast and effective treatment of breakthrough pain in cancer patients. Edluar is based on Orexo's sublingual tablet technology and the active substance zolpidem and offers treatment for short-term insomnia. Diabact UBT is used to diagnose the presence of Helicobacter pylori, the bacterium that causes gastric ulcers. Heliprobe System is a 'doctor's office test' for the presence of the gastric ulcer bacterium, Helicobacter pylori.